节点文献

卵巢癌腹水的过继性细胞免疫治疗

ADOPTIVE CELLULAR IMMUNOTHERAPY IN THE TREATMENT OF OVARIAN CARCINOMA WITH MALIGNANT ASCITES

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 李金锋郭静文林本耀姚丽华

【Author】 Li Jinfeng; Lin Benyao; Guo Jingwen et al (Tangshan Tumor Hospital, Tangshan 063000)

【机构】 河北省唐山市肿瘤医院!063001北京市肿瘤防治研究所

【摘要】 对20例卵巢癌合并恶性腹水的患者提取股水中的肿瘤浸润淋巴细胞(TIL),在体外经重组白细胞介素2(rIL-2)诱导、扩增后回输病人腹腔。培养前后测定淋巴细胞亚群CD3、CD4、CDS、IL-2受体及细胞毒活性,并对TIL/rIL-2治疗前后的腹水病理细胞、CEA及CA125的变化进行监测。结果表明:腹水TIL经培养扩增后,CD8、IL-2受体及细胞毒活性明显增加(P<0.01),腹水CEA及CA125水平均有不同程度下降.部分患者腹水病理细胞消失。经本法治疗腹水消失者占60%,总有效率80%,随访1~6月未见明显毒、副作用。

【Abstract】 This essay presents the treatment of 20 cases suffering from ovarian carcinoma complicated with malignant ascites. Tumor infiltrating lymphocytes (TIL) were abstracted and back-transfused after being induced and expanded in vitro via recombined interleukin-2 (rIL-2). The cytotoxic activity,phenotype and IL-2 receptor (IL-2R) were investigated in fresh,and CEA,CA125 as well as cytology of malignant ascites were determined anterior and posterior to the treatment with TIL/rIL-2. The results show that the cytotoxic sctivity of TIL and CDS,IL-2 as well as cell proliferation were remarkably improved,while CEA and CA125 levels were decreased in all the patients and partly became normal. The ascites disappeared in 60% with total effective rate of 80% and no serious toxicity or side effects were discovered during the follow-up visit of 1-6 months. It is concluded that the TIL. as a new kind of immunocyte,can be safely and effectively used in the treatment of ovarian carcinloma with malignant ascites.

  • 【文献出处】 综合临床医学 ,Clinical Medicine of China , 编辑部邮箱 ,1997年06期
  • 【分类号】R737.31
  • 【被引频次】2
  • 【下载频次】74
节点文献中: 

本文链接的文献网络图示:

本文的引文网络